Overview

Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Calcium heparin
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin